title: Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.
abstract: Design and synthesis of potent MC4 selective agonists based on cyclohexylpiperidine derived cyclic urea, oxazolidinones, and sulfonamide based privileged structures are disclosed.
authors.affiliation: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. Raman_bakshi@merck.com
authors.forename: Raman K
authors.initials: RK
authors.lastname: Bakshi
authors.forename: Qingmei
authors.initials: Q
authors.lastname: Hong
authors.forename: Rui
authors.initials: R
authors.lastname: Tang
authors.forename: Rubana N
authors.initials: RN
authors.lastname: Kalyani
authors.forename: Tanya
authors.initials: T
authors.lastname: Macneil
authors.forename: David H
authors.initials: DH
authors.lastname: Weinberg
authors.forename: Lex H T
authors.initials: LH
authors.lastname: Van der Ploeg
authors.forename: Arthur A
authors.initials: AA
authors.lastname: Patchett
authors.forename: Ravi P
authors.initials: RP
authors.lastname: Nargund
mesh_terms: D015195:Drug Design; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists* / Q000378:metabolism*; D012680:Sensitivity and Specificity; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
chemical_list: D008024:Ligands; C470072:MC4R protein, human; D044105:Receptor, Melanocortin, Type 4